Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Fesoterodin, ATC G04BD11 für die Zeit 01.08.2026 - 31.07.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Opportunity Score
Confidence: 60%
Complexity: low
1086 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Non-exclusive discount agreement for Fesoterodin (ATC G04BD11) under an open-house model by DAK-Gesundheit. Any qualified pharmaceutical company can join at any time during the contract period (01.08.2026–31.07.2028, plus optional 12-month extension). The procedure is not subject to standard procurement law but published for transparency. The estimated value is symbolic (1 EUR).
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Submit offer letter, signed contract, and completed Annex 1 and Annex 2 (Annex 2 must be Excel) via email to [email protected].
- All documents must be in German.
- No postal submissions; only email submissions accepted.
Buyer
Lots (1)
Non-exclusive discount agreement for Fesoterodin drugs. Companies can join at any time by submitting required documents via email. The contract ends automatically if an exclusive contract is awarded.
Procurement Details
Publication
14 Jun 2026
Deadline
05 Jun 2029, 10:00
Procedure
open
Contract
supplies
Duration
24 MONTH
Language
DEU
Publication #
406821-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: low
1086 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation